European Pharmaceutical Law Review - EPLR

The European Pharmaceutical Law Review (EPLR) identifies and analyses important legal and regulatory developments on the national, EU and international level. Furthermore, it provides an overview of and critically examines judgments that shape the interpretation and application of EU pharmaceutical law and policy, in particular those by the European Courts, international courts and tribunals such as the WTO's Dispute Settlement Body, and higher national courts.

In order to establish itself as a forum for dialogue between different stakeholders in pharmaceutical regulation and governance, EPLR invites contributions from academics, practitioners, regulators and civil society representatives.

Topics covered by EPLR include:

• pharmaceutical law and policy in all jurisdictions (regional, national, international);
• Commission decisions (EMA opinions) and regulatory guidelines;
• national, EU, and international jurisprudence;
• medical devices;
• borderline cases: pharmaceuticals/food/cosmetics/chemicals
• patents /trademarks;
• health technology assessment and pricing/reimbursement;
• digital health/big data;
  
  

All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines.

The quarterly journal addresses everyone who is concerned with pharmaceutical law and policy issues such as academics (in the field of law, pharmacy and medicine, regulatory science, and other relevant research fields), legal practitioners in national and international law firms, regulators such government officials working in EU and national public administration, judges and legal experts in domestic, European and international courts, consultancies, business people in the EU and beyond as well as stakeholder organisations representing professionals, patients, and civil society.

As of Issue 1/2022 the "European Pharmaceutical Law Review" (EPLR) will be known as the "European Health and Pharma Law Review" (EHPL).